Media releases Keyword Search Clear 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more Published on: 30 January 2020 Roche reports very strong results in 2019 more Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more
Published on: 14 February 2020 China National Medical Products Administration grants approval of Roche’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer more
Published on: 10 February 2020 Roche provides topline results from investigator-led Phase II/III trial with gantenerumab in rare inherited form of Alzheimer’s disease more
Published on: 6 February 2020 Roche’s risdiplam showed significant improvement in motor function in people aged 2-25 with type 2 or 3 spinal muscular atrophy more
Published on: 27 January 2020 Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer more
Published on: 24 January 2020 Roche provides an update on Phase III study of Tecentriq in people with muscle-invasive urothelial cancer more
Published on: 23 January 2020 Roche’s Risdiplam meets primary endpoint in pivotal FIREFISH trial in infants with type 1 spinal muscular atrophy more
Published on: 21 January 2020 European Commission approves Roche’s Polivy for people with previously treated aggressive lymphoma more
Published on: 13 January 2020 Roche and Illumina partner to broaden patient access to genomic testing more